The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC).
Fernando Rivera
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche
Research Funding - Amgen; Roche
Lee Steven Schwartzberg
Consultant or Advisory Role - Amgen
Meinolf Karthaus
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche
Other Remuneration - Amgen; Roche
Gianpiero Fasola
Consultant or Advisory Role - Amgen
Jean-Luc Canon
Consultant or Advisory Role - Amgen
J. Randolph Hecht
Consultant or Advisory Role - Amgen
Ying Tian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Hua Yu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Kelly Smith Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
William Y. Go
Employment or Leadership Position - Amgen
Stock Ownership - Amgen